The Maryland Prescription Drug Affordability Commission has agreed to set payment limits for the Ozempic diabetes drug, marking the second time the state commission has taken such action in recent weeks.
The board is designed to function like a state utility commission and will oversee the process of lowering the cost of type 2 diabetes drugs for state and local governments by January 2027. At that time, the price would be capped at $274 for a 30-day supply, which the board estimates would save $5.8 million annually.
The projected costs are based on the maximum fair price paid by Medicare, said Andrew York, executive director of the Maryland Board of Regents. Meanwhile, the board plans to take action in 2028 to set payment limits for high-cost drugs that all Marylanders also buy on the commercial insurance market.
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article and get in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
